← brief for 2026-08-26 · Slowing decline

FDA label: 1 INDICATIONS AND USAGE INPEFA is indicated to reduce the ri

Drug label No results yet Not peer reviewed

Key takeaways

The FDA label for INPEFA (sotagliflozin) covers adults with heart failure, or with type 2 diabetes plus chronic kidney disease and other heart risk factors. The drug is a type of SGLT2 inhibitor, a class that lowers blood sugar and also protects the heart and kidneys. The label says it is meant to lower the risk of dying from heart causes and of hospital visits for heart failure. A drug label is a regulatory document, not a study, so there are no new results here.

Source

Drug label · openFDA, renal drug labels · 2026-08-12
https://open.fda.gov/